2018

150 руб.

Фибрилляция предсердий как фактор риска развития когнитивных нарушений и деменции. Возможности антикоагулянтной терапии в их профилактике

Остроумова О. Д.1, 2, Черняева М. С.3, Головина О. В.4
1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А. И. Евдокимова» Минздрава России, Москва, Россия
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
3 ФГБУ ДПО «Центральная государственная медицинская академия» УД Президента России, Москва, Россия
4 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия

Ключевые слова: фибрилляция предсердий, когнитивные функции, когнитивные нарушения, деменция, пожилой и старческий возраст, прямые пероральные антикоагулянты, ривароксабан

DOI: 10.18087/cardio.2018.9.10173

За последние годы накоплены данные относительно возможных ассоциаций между когнитивными нарушениями (КН) и фибрилляцией предсердий (ФП). Данная статья представляет обзор отечественной и зарубежной литературы, включающий современную классификацию КН, механизмы влияния ФП на снижение когнитивных функций и развитие деменции, рекомендации по профилактике КН у пациентов с ФП. Особое внимание уделено оценке когнитивного статуса и безопасной антикоагулянтной терапии, что является приоритетным в профилактике КН у пациентов с ФП. Анализ литературы показал большую эффективность и безопасность препаратов из группы прямых пероральных антикоагулянтов, в частности, ривароксабана по сравнению с варфарином, который может быть рекомендован пожилым пациентам с ФП для профилактики инсульта, КН и деменции.
  1. Chugh S. S., Havmoeller R., Narayanan K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129 (8):837–847. https://dx.DOI.org/10.1161/CIRCULATIONAHA.113.00511
  2. Colilla S., Crow A., Petkun W. et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U. S. adult population. American Journal of Cardiology 2013;112 (8):1142–1147. https://dx.DOI.org/10.1016/j.amjcard.2013.05.063
  3. Bjorck S., Palaszewski B., Friberg L., Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke 2013;44 (11):3103–3108. https://dx.DOI.org/ 10.1161/STROKEAHA.113.002329
  4. Haim M., Hoshen M., Reges O. et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. Journal of the American Heart Association 2015;4 (1):e001486. https://dx.DOI.org/ 10.1161/JAHA.114.001486
  5. Wolf P. A., Abbott R. D., Kannel W. B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22 (8):983–988.
  6. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Russian Journal of Cardiology 2017;7:7–86. Russian http://dx.DOI.org/ 10.15829/1560‑4071‑2017‑7‑7‑86 (Рекомендации ESC по лечению пациентов с фибрилляцией предсердий, разработанные совместно с EACTS. Российский кардиологический журнал 2017;7:7–86.)
  7. Trubin V., Nikolaeva N., Paleeva M., Gavdifattova S. The elderly population of Russia: problems and prospects. Social Bulletin 2016;5:3–45. Russian (Трубин В., Николаева Н., Палеева М., Гавдифаттова С. Пожилое население России: проблемы и перспективы. Социальный бюллетень 2016;5:3–45.)
  8. Steffel J., Verhamme P., Potpara T. S. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace 2018;19:1–12. https://DOI.org/ 10.1093/europace/euy054
  9. European Heart Rhythm Association (EHRA) / Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice? Journal of Arrhythmia 2018;34 (2):99–123. https://DOI.org/ 10.1002/joa3.12050
  10. Diagnostic and statistical manual of mental diseases (DSM–V). 5th ed. London: American Psychiatric Association; 2013. 970 p.
  11. Jelic V., Kivipelto M., Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. Journal of Neurology, Neurosurgery and Psychiatry 2006;77 (4):429–438. https://DOI.org/ 10.1136/jnnp.2005.072926
  12. Zakharov V. V. Cognitive Impairment no Dementia: Classification, Major Causes, and Treatment. Effektivnaya farmakoterapiya. Nevrologiya i psihiatriya 2016;1:22–30. Russian (Захаров В. В. Когнитивные расстройства без деменции: классификация, основные причины и лечение. Эффективная фармакотерапия. Неврология и психиатрия 2016;1:22–30.)
  13. Jessen F., Amariglio R. E., van Boxtel M. et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s and Dementia 2014;10 (6):844–852. https://DOI.org/ 10.1016/j.jalz.2014.01.001
  14. Yahno N. N., Zaharov V. V., Lokshina A. B. et al. Dementia: guidelines for doctors. Moscow: MED press-inform; 2011. 272 p. Russian (Яхно Н. Н., Захаров В. В., Локшина А. Б., и др. Деменции: руководство для врачей. М.: МЕДпреcс-информ; 2011. 272 с.)
  15. Damulin I. V. Cognitive disorder. Some issues of clinical picture, diagnosis, therapy. Moscow; 2012. 19 p. Russian (Дамулин И. В. Когнитивные расстройства. Некоторые вопросы клиники, диагностики, лечения. М.; 2012. 19 с.)
  16. Prince M., Bryce R., Albanese E. et al. The global prevalence of dementia: a systematic review and meta-analysis. Alzheimer’s and Dementia 2013;9 (1):63–75. https://DOI.org/ 10.1016/j.jalz.2012.11.007
  17. Madureira S., Guerreiro M., Ferro J. M. Dementia and cognitive impairment three months after stroke. European Journal of Neurology 2001;8 (6):621–627.
  18. Pasquier F., Leys D. Why are stroke patients prone to develop dementia? Journal of Neurology 1997;244 (3):135–142.
  19. Xu A., Lin Y., Genq J. L. et al. The prevalence and risk factors for cognitive impairment following ischemic stroke. Zhanghua Nei Za Zhi 2008;47 (12):981–984.
  20. Pendlebury S. T., Rothwell P. M. Prevalence, incidence and factors associated with prestrike and post-stroke dementia: a systematic review and meta-analysis. The Lancet. Neurology 2009;8(11):1006–1018. https://DOI.org/ 10.1016/S1474–4422(09)70236–4
  21. Lin H. J., Wolf P. A., Beiser A. S. et al. Incidence of dementia after stroke: the Framingham study. Neurology 1997;48 (3, suppl. 2):A283.
  22. Klimov L. V., Parfenov V. A. Cognitive impairment in the acute period of ischemic stroke. Nevrologicheskii Zhurnal 2006;11(suppl. 1):53–56. Russian (Климов Л. В., Парфенов В. А. Когнитивные нарушения в остром периоде ишемического инсульта. Неврологический журнал 2006;11 (прил. 1):53–56.)
  23. Levin O. S., Usoltseva N. I. Risk factors and dynamics of cognitive impairment in the early recovery period of ischemic stroke. Klinicheskaya Nevrologiya 2007;2:3–5. Russian (Левин О. С., Усольцева Н. И. Факторы риска и динамика когнитивных нарушений в раннем восстановительном периоде ишемического инсульта. Клиническая неврология 2007;2:3–5.)
  24. Levin O. S., Usoltseva N. I., Dudarova M. A. Cognitive disorders in the early rehabilitative period of ischemic stroke. Medical Journal of the Russian Federation, Russian Journal 2009;4:20–25. Russian (Левин О. С., Усольцева Н. И., Дударова М. А. Когнитивные нарушения в раннем восстановительном периоде ишемического инсульта. Российский медицинский журнал 2009;4:20–25.)
  25. Zakharov V. V., Vakhnina N. V. Stroke and cognitive disorders. Neurology, Neuropsychiatry, Psychosomatics 2011;2:8–16. Russian (Захаров В. В., Вахнина Н. В. Инсульт и когнитивные нарушения. Неврология, нейропсихиатрия, психосоматика 2011;2:8–16.)
  26. Kwok C. S., Loke Y. K., Hale R. et al. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology 2011;76 (10):914–922. https://DOI.org/ 10.1212/WNL.0b013e31820f2e38
  27. Kalantarian S., Stern T. A., Mansour M., Ruskin J. N. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Annals of Internal Medicine 2013;158 (5Pt1):338–346. https://DOI.org/ 10.7326/0003‑4819‑158‑5‑201303050‑00007
  28. Santangeli P., Di Biase L., Bai R. et al. Atrial fibrillation and the risk of incident dementia: a meta-analysis. Heart Rhythm 2012;9 (11):1761–1768. https://DOI.org/ 10.1016/j.hrthm.2012.07.026
  29. Chen L. Y., Agarwal S. K., Norby F. L. et al. Persistent but not paroxysmal atrial fibrillation is independently associated with lower cognitive function: ARIC Study. Journal of the American College of Cardiology 2016;67 (11):1379–1380. https://DOI.org/ 10.1016/j.jacc.2015.11.064
  30. Gaita F., Corsinovi L., Anselmino M. et al. Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function. Journal of the American College of Cardiology 2013;62 (21):1990–1997. https://DOI.org/ 10.1016/j.jacc.2013.05.074
  31. Satizabal C. L., Beiser A. S., Chouraki V., Chene G., Dufouil C., Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. The New England Journal of Medicine 2016;374 (6):523–532. https://DOI.org/ 10.1056/NEJMoa1504327.
  32. Kalantarian S., Ruskin J. N. Atrial fibrillation and cognitive decline: phenomenon or epiphenomenon? Cardiology Clinics 2016;34(2):279–285. https://DOI.org/ 10.1016/j.ccl.2015.12.011
  33. Mozaffarian D., Benjamin E. J., Go A. S. et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015;131 (4):e29–e32. https://DOI.org/ 10.1161/CIR.0000000000000152
  34. Gorelick P. B., Scuteri A., Black S. E. et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42 (9):2672–2713. https://DOI.org / 10.1161/STR.0b013e3182299496
  35. Graves K. G., May H. T., Jacobs V. et al. Atrial fibrillation incrementally increases dementia risk across all CHADS2 and CHA2DS2VASc strata in patients receiving long-term warfarin. American Heart Journal 2017;188:93–98. https://DOI.org / 10.1016/j.ahj.2017.02.026
  36. January C. T., Wann L. S., Alpert J. S. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130 (23):2071–2104. https://DOI.org / 10.1161/CIR.0000000000000040
  37. Ott A., Breteler M. M., de Bruyne M. C. et al. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997;28 (2):316–321.
  38. Kilander L., Andren B., Nyman H. et al. Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men. Stroke 1998;29 (9):1816–1820.
  39. Thacker E. L., McKnight B., Psaty B. M. et al. Atrial fibrillation and cognitive decline: a longitudinal cohort study. Neurology 2013;81 (2):119–125. https://DOI.org / 10.1212/WNL.0b013e31829a33d1
  40. Bunch T. J., Weiss J. P., Crandall B. G. et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer’s dementia. Heart Rhythm 2010;7 (4):433–437. https://DOI.org /10.1016/j.hrthm.2009.12.004
  41. de Bruijn R. F., Heeringa J., Wolters F. J. et al. Association between atrial fibrillation and dementia in the general population. JAMA Neurol 2015;72 (11):1288–1294. https://DOI.org /10.1001/jamaneurol.2015.2161
  42. Coma M., Gonzalez-Moneo M. J., Enjuanes C. et al. Effect of permanent atrial fibrillation on cognitive function in patients with chronic heart failure. The American Journal of Cardiology 2016;117(2):233–239. https://DOI.org / 10.1016/j.amjcard.2015.10.038
  43. Proietti M., Recchia A., Riva E. et al. Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older. European Journal of Internal Medicine 2017;46:6–10. https://DOI.org / 10.1016/j.ejim.2017.08.010
  44. Vermeer S. E., Den Heijer T., Koudstaal P. J. et al. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2003;34 (2):392–396.
  45. Kalantarian S., Ay H., Gollub R. L. et al. Association between atrial fibrillation and silent cerebral infarctions: a systematic review and meta-analysis. Annalsof Internal Medicine 2014;161 (9):650–658. https://DOI.org / 10.7326/M14–0538
  46. Vermeer S. E., Prins N. D., den Heijer T. et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348(13):1215–1222. https://DOI.org / 10.1056/NEJMoa022066
  47. Choudhury N. A., DeBaun M. R., Rodeghier M. et al. Silent cerebral infarct definitions and full-scale IQ loss in children with sickle cell anemia. Neurology 2018;90 (3):e239–e246. https://DOI.org / 10.1212/WNL.0000000000004832
  48. Konno S., Meyer J. S., Terayama Y. et al. Classification, diagnosis and treatment of vascular dementia. Drugs and Aging 1997;11(5):361–373.
  49. Chen L. Y., Lopez F. L., Gottesman R. F. et al. Atrial fibrillation and cognitive decline-the role of subclinical cerebral infarcts: the atherosclerosis risk in communities study. Stroke 2014;45 (9):2568–2574. https://DOI.org / 10.1161/STROKEAHA.114.005243
  50. Goette A., Kalman J. M., Aguinaga L. et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace 2016;18(10):1455–1490. https://DOI.org / 10.1093/europace/euw161
  51. Poggesi A., Inzitari D., Pantoni L. Atrial fibrillation and cognition: epidemiological data and possible mechanisms. Stroke 2015;46(11):3316–3321. https://DOI.org / 10.1161/STROKEAHA.115.008225
  52. Stefansdottir H., Arnar D. O., Aspelund T. et al. Atrial fibrillation is associated with reduced brain volume and cognitive function independent of cerebral infarcts. Stroke 2013;44 (4):1020–1025. https://DOI.org / 10.1161/STROKEAHA.12.679381.
  53. Gardarsdottir M., Sigurdsson S., Aspelund T. et al. Atrial fibrillation is associated with decreased total cerebral blood flow and brain perfusion. Europace 2017;10:1–7. https://DOI.org / 10.1093/europace/eux220.
  54. Mielke M. M., Rosenberg P. B., Tschanz J. et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007;69(19):1850–1858. https://DOI.org / 10.1212/01.wnl.0000279520.59792.fe
  55. Rocken C., Peters B., Juenemann G. et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002;106 (16):2091–2097.
  56. Wardlaw J. M., Smith C., Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet. Neurology 2013;12 (5):483–497. https://DOI.org / 10.1016/S1474–4422(13)70060–7
  57. Poggesi A., PasiM., Pescini F. et al. Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: a review. Journal of Cerebral Blood Flow and Metabolism 2016;36 (1):72–94. https://DOI.org / 10.1038/jcbfm.2015.116
  58. Brodaty H., Pond D., Kemp N. M. et al. The GPCOG: a new screening test for dementia designed for general practice. Journal of American Geriatrics Society 2002;50 (3):530–534.
  59. Folstein M. F., Folstein S. E., McHugh P. R. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12 (3):189–198.
  60. Nasreddine Z. S., Phillips N. A., Bédirian V. A. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of American Geriatrics Society 2005;53(4):695–699. https://DOI.org / 10.1111/j.532–5415.2005.53221.x
  61. Jorm A. F., Jacomb P. A. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychological Medicine 1989;19 (4):1015–1022.
  62. Friberg L., Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. European Heart Journal 2018;39 (6):453–460. https://DOI.org / 10.1093/eurheartj/ehx579
  63. Woller S. C., Stevens S., May H. T. et al. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm 2014;11 (12):2206–2213. https://DOI.org / 10.1016/j.hrthm.2014.08.013
  64. Fratiglioni L., Paillard-Borg S., Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet. Neurology 2004;3 (6):343–353. https://DOI.org /10.1016/S1474–4422(04)00767–7
  65. Bunch T. J., May H. T., Bair T. L. et al. Dementia rates increase with delays in initiation of anticoagulation treatment for atrial fibrillation. Heart Rhythm 2017;14:S73.
  66. Ferland G., Feart C., Presse N. et al. Vitamin K Antagonists and Cognitive Function in Older Adults: The Three-City Cohort Study. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2016;71 (10):1356–62. https://DOI.org / 10.1093/gerona/glv208
  67. Nevado-Holgado A. J., Kim C. H., Winchester L. et al. Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open 2016;6 (11):e012177. https://DOI.org / 10.1136/bmjopen-2016–012177
  68. Kirchhof P., Haeusler K. G., Blank B. et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. European Heart Journal 2018; Mar 20:1–14. https://DOI.org / 10.1093/eurheartj/ehy176. [Epub ahead of print]
  69. Bellmann B., Fiebach J. B., Guttmann S. et al. Incidence of MRIdetected brain lesions and neurocognitive function after electrical cardioversion in anticoagulated patients with persistent atrial fibrillation. International Journal of Cardiology 2017;243:239–243. https://DOI.org/10.1016/j.ijcard.2017.05.102 
  70. Saito T., Kawamura Y., Sato N. et al. Nonvitamin K antagonist oral anticoagulants do not increase cerebral microbleeds. J Stroke Cerebrovasc Dis 2015;24 (6):1373–1377. https://DOI.org / 10.1016/j.jstrokecerebrovasdis.2015.02.018
  71. Ruff C. T., Giugliano R. P., Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet (London, England) 2014;383 (9921):955–962. https://DOI.org / 10.1016/S0140–6736(13)62343–0
  72. Jacobs V., May H. T., Bair T. L. et al. Long-term population-based cerebral ischemic event and cognitive outcomes of direct oral anticoagulants compared with warfarin among long-term anticoagulated patients for atrial fibrillation. Am J Cardiol 2016;118 (2):210–214. https://DOI.org / 10.1016/j.amjcard.2016.04.039
  73. Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF) [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03061006 (10 Feb 2018).
  74. Cognitive Impairment Related to Atrial Fibrillation Prevention Trial (GIRAF) [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT01994265 (10 Feb 2018).
  75. Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST) [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT01288352 (10 Feb 2018).
  76. NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH (NASPAF-ICH) [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT02998905 (10 Feb 2018).
  77. Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial (OCEAN) [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT02168829 (10 Feb 2018).
  78. Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF (BRAINAF) [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT02387229 (10 Feb 2018).
  79. Kato E. T., Giugliano R. P., Ruff C. T. et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 Trial. Journal of the American Heart Association 2016;5 (5):e003432. https://DOI.org / 10.1161/JAHA.116.003432
  80. Halperin J. L., Hankey G. J., Wojdyla D. M. et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014;130 (2):138–146. https://DOI.org / 10.1161/CIRCULATIONAHA.113.005008
  81. Halvorsen S., Atar D., Yang H. et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014;35 (28):1864–1872. https://DOI.org / 10.1093/eurheartj/ehu046
  82. Xue Q. L. The Frailty Syndrome: Definition and Natural History. Clinics in Geriatric Medicine 2011;27 (1):1–15. https://DOI.org / 10.1016/j.cger.2010.08.009
  83. MIDAS [Internet]. Available from: https://www.iqvia.com (10 Feb 2018).
  84. Connolly S. J., Ezekowitz M. D., Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. The New England Journal of Medicine 2009;361 (12):1139–1151. https://DOI.org / 10.1056/NEJMoa0905561
  85. Fox K. A., Piccini J. P., Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvularatrial fibrillation and moderate renal impairment. European Heart Journal 2011;32 (19):2387–2394. https://DOI.org / 10.1093/eurheartj/ehr342
  86. Yao X., Shah N. D., Sangaralingham L. R. et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. Journal of the American College of Cardiology 2017;69 (23):2779–2790. https://DOI.org / 10.1016/j.jacc.2017.03.600
  87. Camm A. J., Amarenco P., Haas S. et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. European Heart Journal 2016;37 (14):1145–1153. https://DOI.org / 10.1093/eurheartj/ehv466
  88. Hecker J., Marten S., Keller L. et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thrombosis and Haemostasis 2016;115 (5):939–949. https://DOI.org / 10.1160/TH15‑10‑0840
  89. Laliberté F., Cloutier M., Nelson W. W. et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Current Medical Research and Opinion 2014;30 (7):1317–1325. https://DOI.org / 10.1185/03007995.2014.907140
  90. Nelson W. W., Song X., Coleman C. I. et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Current Medical Research Opinion 2014;30 (12):2461–2469. https://DOI.org / 10.1185/03007995.2014.933577
  91. Nelson W. W., Song X., Thomson E. et al. Medication Persistence and Discontinuation of Rivaroxaban and Dabigatran Etexilate among Patients with Non-Valvular Atrial Fibrillation. Current Medical Research Opinion 2015:31 (10):1831–1840. https://DOI.org / 10.1185/03007995.2015.1074064
  92. Hankey G. J., Patel M. R., Stevens S. R. et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet. Neurology 2012;11 (4):315–322. https://DOI.org / 10.1016/S1474–4422(12)70042‑X
  93. Connolly S. J., Ezekowitz M. D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine 2009;361 (12):1139–1151. https://DOI.org / 10.1056/NEJMoa0905561
  94. Granger C. B., Alexander J. H., McMurray J. J. et al. Apixaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine 2011;365 (11):981–992. https://DOI.org / 10.1056/NEJMoa1107039
  95. Patel M. R., Mahaffey K. W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine 2011;365 (10):883–991. https://DOI.org / 10.1056/NEJMoa1009638
  96. Parfyonov V. A., Verbitskaya S. V. Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study. Meditsinskiy Sovet 2014;5:6–11. Russian (Парфенов В. А., Вербицкая С. В. Вторичная профилактика ишемического инсульта при фибрилляции предсердий. Результаты исследования ROCKET AF. Медицинский совет 2014;5:6–11.)
  97. Kelly-Hayes M., Beiser A., Kase C. S. et al. The influence of gender and age on disability following ischemic stroke: the Framingham study. Journal Stroke Cerebrovascular Diseases 2003;12 (3):119–126. https://DOI.org / 10.1016/S1052–3057(03)00042–9
  98. Graff J., von Hentig N., Misselwitz F. et al. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. Journal of Clinical Pharmacology 2007;47 (11):1398–1407. https://DOI.org / 10.1177/0091270007302952
  99. Stroke & Cognition [Internet]. Available from: http://www.phri.ca/research/stroke-cognition/navigate-esus/ (10 Feb 2018).
Остроумова О. Д., Черняева М. С., Головина О. В. Фибрилляция предсердий как фактор риска развития когнитивных нарушений и деменции. Возможности антикоагулянтной терапии в их профилактике. Кардиология. 2018;58(9):76–88.

Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
Ru En